For Better User Experience Please Use Potrait Mode.

Our Science
Team
Overview
About Us

Founded in 2011, OncoStem Diagnostics aims to develop innovative multi-marker prognostic tests to carefully personalize treatments for breast cancer patients.

Cancer is a complex disease and, at OncoStem, we develop tests that help identify patterns of recurrence. An understanding of these patterns ensures that patients receive therapies and treatments tailor-made to their condition.

Our approach to cancer research and diagnosis involves integrating the molecular signature of the disease with clinicopathological parameters. This time-tested methodology allows us to accurately predict the course of the cancer.

Our expertise in tumor biology assists physicians in developing optimal therapeutic plans for patients. We utilize gold-standard protein or gene expression techniques in our assays and combine them with a deep learning approach to further our understanding of cancer.

CanAssist-Breast, a test created by OncoStem, identifies the risk of breast cancer recurrence. Every test developed in our labs has been designed with the intention aiding targeted therapies.

OncoStem is currently working on similar tests for oral, lung, and colorectal cancer. Research is underway towards identifying and characterizing novel drug targets for breast and oral cancer. 

Leadership
Manjiri Bakre, Ph D
CEO & Founder

Dr. Bakre –A Cell Biology and Cell Signaling veteran has 18 years experience in research and technology in India, US and Singapore. She founded OncoStem with the vision of developing and delivering innovative, cost effective and reliable tests for personalized cancer treatment planning. Previously she has worked in academia at Mt Sinai School of Medicine, NYC and Moores Cancer Center, UCSD and in the industry as well. Last job at Philips Research involved the development of Point of Care diagnostics. She has won many awards including Young Scientist, paper of the week etc published in Nature Medicine and has multiple patents.

Satyanarayana Thallam
Chief Operating Officer

Take-charge Leader offering 24 years of diversified experience that reflects year-on-year success in achieving business growth objectives by leveraging entrepreneurial drive and diversified acumen
Operational Expertise in strengthening operational efficiency, performance enhancement and effective stakeholder management
History of excelling in introducing new organizational change, expanding markets and leveraging existing knowledge base with internal resources to facilitate business excellence
Excelled in managing business operations with focus on top-line & bottom-line performance and expertise in determining company’s mission & strategic direction as conveyed through policies & corporate objectives

Chetana Basavaraj
Lab Director

Dr. Chetana Basavaraj has had immense experience of 18 years as a pathologist. She has worked as a faculty at Dr. Ambedkar Medical College Bangalore followed by a stint of 9 years at Clinigene International Ltd a Biocon company where she was associated with a number of clinical trial projects and proof of concept studies involving histopathology and immunohistochemistry. Her special interest was in Epidermal growth factor receptor and its signaling pathways with IHC analysis in Head & Neck tumors.

Nanjunda Prasad
Vice President, Marketing and Business Development

Nanjunda Prasad is responsible for Marketing and Business Development at OncoStem. He has extensive experience in conceptualizing and taking differentiated products to market spanning varied domains such as Healthcare, Artificial Intelligence and Cloud. Previously, he has worked with R&D teams at Siemens and Philips healthcare, focussing on specialized medical devices for Oncology. His management experience is backed by business education in strategy and marketing.

Scientific Advisors
Dr. Sudeep Gupta

Dr. Sudeep Gupta, completed his MBBS, MD and DM from All India Institute of Medical Sciences, New Delhi, in the year 2000 and has been a faculty member in the Department of Medical Oncology at Tata Memorial Centre since then. He has been a prolific clinical researcher who is actively involved in planning, organizing, conducting and analyzing Phase I, II and III clinical trials and has been a Principal Investigator or Co-investigator in more than 100 trials. He takes special interest in breast and gynecological cancers and early drug development. His research areas have involved implementation science including access to medications, guideline development, testing concepts and technology in clinical trials, innovative therapeutic strategies, toxicity and quality-of-life studies, pharmacokinetics and translational studies involving next-generation sequencing technology. He has published more than 120 papers in peer reviewed journals. Since 2013 he has been the Deputy Director of the Advanced Centre for Treatment, Research and Education in Cancer (ACTREC) one of the premier cancer translational researchcentres in India. He is currently engaged in facilitating cross talk between various stakeholders in cancer research at the institutional and national level, including basic scientists, clinical researchers, computational biologists, physicists, engineers and others.

Dr. Harit Chaturvedi

Dr.Harit Chaturvedi is the Chief Consultant and Director of Surgical Oncology at Max HealthCare, leading a team of 80 Oncologists spread over 7 multi-specialty centers. He received his MBBS and MS degrees from G.S.V.M Medical College, Kanpur and M.Ch. (Surgical Oncology) from M.G.R. Medical University, Chennai. He has worked at several specialty cancer centers in India including Kidwai Memorial Institute, Bangalore, Adyar Cancer Center (Chennai) and the Rajiv Gandhi Cancer Institute (Delhi). He has several publications in national and International journals and is a keen champion of research initiatives in India.

Investment Advisors
Anjana Sasidharan

Anjana is a Principal with Sequoia Capital India. She focuses on investments in the consumer and healthcare sectors. Prior to joining Sequoia, Anjana spent four years with McKinsey & Company. At McKinsey she advised clients across multiple sectors in India on Strategy, as well as Sales & Marketing. Anjana holds an MBA from the Indian Institute of Management, Ahmedabad and a BS in Electronics & Communication Engineering from the National Institute of Technology, Tiruchirappalli.

Akhil Saklecha

Akhil Saklecha focuses on early-stage investments with an interest towards medical technology. As a Partner at Artiman, he has led investments in CellMax Life, DMS Networks, HomeUnion, Slive and ApplyBoard.
Akhil has over 20+ years of experience in medicine and healthcare management. Prior to joining Artiman in 2010, Akhil was Medical Director of a 750 bed hospital's regional transfer program. Prior to that position, he was President and CEO of Canton Aultman Emergency Physicians, a professional services firm that provides physicians, mid-level providers, and coding expertise to multiple hospitals and urgent care centers. He was also Chairman of Emergency Medicine at Aultman Hospital, a large trauma, cardiac, and stroke center seeing nearly 90,000 patients annually. In this same time period, Akhil has served at the local, state, and national levels within emergency medicine, healthcare quality, information technology, managed care, and emergency medical services.
He is an Assistant Professor in Emergency Medicine at Northeastern Ohio Universities College of Medicine and continues to practice on a part time basis at Good Samaritan Hospital in San Jose where he remains connected to clinical medicine, patients, and physicians.
Akhil graduated from the combined B.S./M.D. program at Northeastern Ohio Universities College of Medicine. He completed his residency in Emergency Medicine at Summa Health System. He is Board Certified in Emergency Medicine and is a Fellow of the American College of Emergency Medicine. He holds an M.B.A. from the University of Tennessee at Knoxville where he graduated Phi Beta Kappa.

Clinical Advisors
Dr. Mark Pegram, MD

Mark D. Pegram is the director of the Breast Cancer Oncology Program at Stanford Women’s Cancer Center. Dr. Pegram earned his undergraduate and medical degrees from the University of North Carolina and worked at University of California, Los Angeles and the University of Miami Miller School of Medicine before moving to Stanford. He is a renowned clinician and scholar in breast cancer research and a leader in translational medicine. Dr. Pegram played a major role in developing the drug Herceptin as a treatment for HER2-positive breast cancer. His work showing that Herceptin improved survival rates and even cured some patients with Breast Cancer is of paramount importance, not only for the emergence of personalized medicine therapy in Breast Cancer, but also highlighting the significance of the translational research.

Dr. Somashekhar S. P.

Dr. Somashekhar S. P. is HOD, Consultant Surgical, Gynec.Onco & Robotic Surgeon in Manipal Comprehensive Cancer Center. He is also a member of Board of studies, Maipal University and a member of Business Advisory Board, MHEPL. His qualifications includes MBBS from Mysore University, MS (Gen. Surgery) from NHL Medical College, MCh (Surgical Oncology) from GCRI. He has multiple prestigious fellowships including (FRCS), Fellow of Royal College of Surgeons, Edinburgh. He received Millenium Gold Medal Award in 2006 ASI, SSB for work in Sentinel Lymph Node. Dr. Somashekher is a recipient of the prestigious Dr. D. D. Patel Gold Medal in Oncosurgery. He has been editor and author of various text books and operative Atlas's on Oncosurgery and Breast surgery, Gynecological oncology & Robotic surgery. He is first in India to initiate Robotic Scarless Thyroidectomy programme & TORS and has done highest number of Robotic Complex Oncosurgeries in India.

Investors

Artiman is an early-stage Silicon Valley-based venture fund that invests in white space companies and also this Venture capital firm provides a pathway to Silicon Valley for aspiring student entrepreneurs with backgrounds in Biology, Economics, Technology, and the Arts.

Sequoia Capital partners both with young companies finding their stride and established ones looking for the next level of growth, helping ventures and ideas become enduring businesses.

Our Science

OncoStem is focused on developing innovative prognostic and predictive solutions for various types of Cancers. Our approach involves integrating the molecular signature of the disease with clinicopathological parameters that are time-tested in prognostic evaluation of cancer. We use our expertise in tumor biology to create actionable solutions that assist physicians in developing optimal therapeutic programs for their patients.

We utilize gold-standard protein or gene expression techniques in our assays and combine them with a deep learning approach that enhances our knowledge of cancer. Our flagship test, CanAssist-Breast is focused on the risk of recurrence prediction in Breast Cancer. We are developing similar tests for Head & Neck and Colon Cancer.

Accreditations
and Licences
ISO 13485:2016
CE Marked under IVD directive
98/79/EC
NABL – ISO 15189:2012,
Certificate No. MC-2814
(Accredited for ER, PgR, Her2/neu and Ki67)